PMC:4143611 / 2314-2980 JSONTXT

Annnotations TAB JSON ListView MergeView

    2_test

    {"project":"2_test","denotations":[{"id":"24980037-14557445-63233395","span":{"begin":184,"end":185},"obj":"14557445"},{"id":"24980037-18413427-63233396","span":{"begin":187,"end":188},"obj":"18413427"},{"id":"24980037-23450054-63233397","span":{"begin":348,"end":349},"obj":"23450054"},{"id":"24980037-20556520-63233398","span":{"begin":351,"end":352},"obj":"20556520"},{"id":"24980037-2303869-63233399","span":{"begin":472,"end":473},"obj":"2303869"},{"id":"24980037-22785183-63233400","span":{"begin":475,"end":476},"obj":"22785183"},{"id":"24980037-18413427-63233401","span":{"begin":536,"end":537},"obj":"18413427"}],"text":"The primary treatment of choice for CD is adenomectomy by transsphenoidal surgery (TSS). Surgical success rates are variable, ranging from 65 to 90 %, and depend on surgeon expertise [2, 3]. Furthermore, criteria and testing parameters for assessing immediate remission vary from center to center, making the interpretation of results challenging [4, 5]. Additionally, post-surgical recurrence of CD is not uncommon, with reported recurrence rates ranging from 3 to 47 % [6, 7], and an observed mean time to recurrence of 16–49 months [3]. For patients in whom pituitary surgery fails or is contraindicated, radiotherapy or medical treatment are alternative options."}